Genscript Biotech Corporation
1548
Rang in aandelen
#2098
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Aandeelprijs
$4.37
Marktkapitalisatie
$9.84B
Verandering (1 dag)
2.30%
Verandering (1 jaar)
109.57%
Land
HK
Handel Genscript Biotech Corporation (1548)
Categorie
Healthcare
Winst voor Genscript Biotech Corporation (1548)
Winst in Jun 2026 TTM: $-589.54M
Volgens de meest recente financiële verslagen van Genscript Biotech Corporation bedraagt de huidige winst van het bedrijf $-589.54M. In 2023 behaalde het bedrijf een winst van $-350.98M, een stijging ten opzichte van de winst van 2022, die $-431.69M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Genscript Biotech Corporation van 2013 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-589.54M | 245.17% |
| 2024 | $-170.80M | -51.34% |
| 2023 | $-350.98M | -18.70% |
| 2022 | $-431.69M | -16.56% |
| 2021 | $-517.36M | 83.53% |
| 2020 | $-281.90M | 147.95% |
| 2019 | $-113.69M | -600.84% |
| 2018 | $22.70M | -41.07% |
| 2017 | $38.52M | 18.49% |
| 2016 | $32.51M | 41.49% |
| 2015 | $22.98M | 193.21% |
| 2014 | $7.84M | 4.08% |
| 2013 | $7.53M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -994.74% |
US
|
|
| $-3.09B | 423.62% |
US
|
|
| $-4.02B | 581.24% |
AU
|
|
| $1.95B | -430.87% |
NL
|
|
| - | - |
CH
|
